Jefferies Group set a GBX 5,075 ($70.12) price objective on AstraZeneca (LON:AZN) in a report released on Monday, February 26th. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.
Other equities research analysts also recently issued reports about the stock. Citigroup reaffirmed a buy rating on shares of AstraZeneca in a report on Wednesday, November 8th. Investec upped their price target on AstraZeneca from GBX 4,900 ($67.70) to GBX 5,500 ($75.99) and gave the company a buy rating in a research report on Monday, November 6th. Berenberg Bank reiterated a buy rating and set a GBX 5,800 ($80.13) price target on shares of AstraZeneca in a research report on Wednesday, November 1st. Deutsche Bank reiterated a buy rating and set a GBX 5,600 ($77.37) price target on shares of AstraZeneca in a research report on Wednesday, November 1st. Finally, Kepler Capital Markets upped their price target on AstraZeneca from GBX 5,200 ($71.84) to GBX 5,250 ($72.53) and gave the company a buy rating in a research report on Wednesday, November 1st. Four research analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. AstraZeneca currently has a consensus rating of Hold and an average price target of GBX 5,199.70 ($71.84).
AstraZeneca (LON AZN) traded down GBX 18 ($0.25) during midday trading on Monday, reaching GBX 4,765 ($65.83). 1,547,547 shares of the company’s stock traded hands, compared to its average volume of 2,310,000. The stock has a market capitalization of $60,110.00 and a P/E ratio of 2,836.31. AstraZeneca has a 1-year low of GBX 4,260 ($58.86) and a 1-year high of GBX 5,520 ($76.26).
The business also recently disclosed a dividend, which will be paid on Monday, March 19th. Investors of record on Thursday, February 15th will be given a GBX 133.60 ($1.85) dividend. This represents a dividend yield of 2.8%. This is a boost from AstraZeneca’s previous dividend of $68.90. The ex-dividend date of this dividend is Thursday, February 15th.
In related news, insider Philip A. J. Broadley acquired 415 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The shares were bought at an average cost of GBX 4,846 ($66.95) per share, for a total transaction of £20,110.90 ($27,785.16).
ILLEGAL ACTIVITY WARNING: This article was posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.thelincolnianonline.com/2018/03/14/astrazeneca-azn-given-a-gbx-5075-price-target-by-jefferies-group-analysts.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.